Spyre Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Spyre Therapeutics
SYRE Stock   22.27  0.37  1.69%   
Spyre Therapeutics financial statements provide useful quarterly and yearly information to potential Spyre Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Spyre Therapeutics financial statements helps investors assess Spyre Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Spyre Therapeutics' valuation are summarized below:
Gross Profit
-84 M
Market Capitalization
1.3 B
Enterprise Value Revenue
2 K
Earnings Share
(37.90)
There are over one hundred nineteen available fundamental trend indicators for Spyre Therapeutics, which can be analyzed over time and compared to other ratios. Investors should ensure to double-check all of Spyre Therapeutics' current performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. The current year's Enterprise Value is expected to grow to about 80.7 M, whereas Market Cap is forecasted to decline to about 114.2 M.

Spyre Therapeutics Total Revenue

757,530

Check Spyre Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Spyre Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.1 M, Total Revenue of 757.5 K or Other Operating Expenses of 293.7 M, as well as many indicators such as Price To Sales Ratio of 168, Dividend Yield of 0.0 or PTB Ratio of 0.94. Spyre financial statements analysis is a perfect complement when working with Spyre Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Spyre Therapeutics Correlation against competitors.
For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.

Spyre Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets412.8 M393.1 M136.1 M
Slightly volatile
Other Current Liabilities37.5 M35.7 M11.7 M
Slightly volatile
Total Current Liabilities18.7 M36.8 M12.5 M
Slightly volatile
Total Stockholder Equity107.9 M211.6 M87.3 M
Slightly volatile
Current Deferred Revenue564.8 K594.5 K2.8 M
Pretty Stable
Accounts Payable1.5 M1 M942.2 K
Slightly volatile
Cash228.1 M217.2 M72.7 M
Slightly volatile
Non Current Assets Total361.6 K380.6 K3 M
Slightly volatile
Non Currrent Assets Other282.7 K331 K177.2 K
Slightly volatile
Other Assets0.80.90.9813
Slightly volatile
Cash And Short Term Investments409.7 M390.2 M129.7 M
Slightly volatile
Net Receivables320.6 K337.5 K983.5 K
Slightly volatile
Common Stock Shares Outstanding7.7 M7.3 M2.2 M
Slightly volatile
Short Term Investments181.6 M172.9 M57 M
Slightly volatile
Liabilities And Stockholders Equity412.8 M393.1 M136.1 M
Slightly volatile
Non Current Liabilities Total152 M144.7 M27.9 M
Slightly volatile
Other Current Assets3.3 M2.6 M2.5 M
Slightly volatile
Other Stockholder Equity921.6 M877.7 M325 M
Slightly volatile
Total Liabilities190.6 M181.5 M41.6 M
Slightly volatile
Total Current Assets412.4 M392.8 M133 M
Slightly volatile
Common Stock12.1 K11.5 K4 K
Slightly volatile
Short and Long Term Debt Total102.1 M97.2 M21.9 M
Slightly volatile
Capital Stock223.3 M212.7 M38.8 M
Slightly volatile
Non Current Liabilities Other49.9 M47.5 M11.3 M
Slightly volatile
Net Working Capital373.8 M356 M116.3 M
Slightly volatile
Short Term Debt483.7 K718.8 K437.3 K
Slightly volatile

Spyre Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.1 M964 K671.8 K
Slightly volatile
Other Operating Expenses293.7 M279.7 M88.6 M
Slightly volatile
Research Development60.7 M102.9 M42.5 M
Slightly volatile
Total Operating Expenses293.7 M279.7 M88.5 M
Slightly volatile
Net Interest Income7.4 M7.1 M2.3 M
Slightly volatile
Interest Income7.4 M7.1 M2.3 M
Slightly volatile
Selling General Administrative32.2 M45.9 M23.4 M
Slightly volatile
Cost Of Revenue1.1 M867.6 K1.1 M
Slightly volatile
Reconciled Depreciation1.2 M855.6 K800.8 K
Slightly volatile

Spyre Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow38.5 M41.9 M33.4 M
Pretty Stable
Depreciation880.2 K855.6 K561.6 K
Slightly volatile
Other Non Cash Items262.8 M250.3 M46.9 M
Slightly volatile
Total Cash From Financing Activities436 M415.2 M118.2 M
Slightly volatile
End Period Cash Flow228.5 M217.6 M73.1 M
Slightly volatile
Stock Based Compensation31 M29.5 M10.2 M
Slightly volatile
Other Cashflows From Investing Activities12.4 M13.9 M15.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio16816046.7911
Slightly volatile
PTB Ratio0.940.9923.6884
Slightly volatile
Days Sales Outstanding10767.5979.9019
Slightly volatile
Book Value Per Share27.3928.8341.3512
Pretty Stable
Stock Based Compensation To Revenue27.3826.085.5514
Slightly volatile
Capex To Depreciation0.02650.02793.87
Slightly volatile
PB Ratio0.940.9923.6884
Slightly volatile
Payables Turnover0.70.970.5559
Slightly volatile
Sales General And Administrative To Revenue42.6140.589.6961
Slightly volatile
Research And Ddevelopement To Revenue95.4690.9221.9206
Slightly volatile
Capex To Revenue0.01780.01880.04
Pretty Stable
Cash Per Share69.8353.1548.5555
Slightly volatile
Days Payables Outstanding3713902.6 K
Slightly volatile
Income Quality0.320.340.7199
Slightly volatile
Net Debt To EBITDA0.950.940.7195
Pretty Stable
Current Ratio8.812.287.4296
Slightly volatile
Tangible Book Value Per Share27.3928.8341.3512
Pretty Stable
Receivables Turnover6.135.598.9454
Slightly volatile
Graham Number239186172
Slightly volatile
Shareholders Equity Per Share27.3928.8341.3512
Pretty Stable
Debt To Equity0.430.410.1465
Slightly volatile
Capex Per Share0.00960.01010.4758
Very volatile
Graham Net Net27.028.4337.8226
Pretty Stable
Revenue Per Share0.130.147.9626
Slightly volatile
Interest Debt Per Share10.8910.374.9192
Slightly volatile
Debt To Assets0.230.220.0911
Slightly volatile
Operating Cycle10767.5979.9019
Slightly volatile
Price Book Value Ratio0.940.9923.6884
Slightly volatile
Days Of Payables Outstanding3713902.6 K
Slightly volatile
Ebt Per Ebit0.841.261.0759
Pretty Stable
Company Equity Multiplier1.061.671.3496
Very volatile
Total Debt To Capitalization0.30.280.1162
Slightly volatile
Debt Equity Ratio0.430.410.1465
Slightly volatile
Quick Ratio8.812.287.4296
Slightly volatile
Net Income Per E B T1.11.151.0171
Slightly volatile
Cash Ratio4.946.794.4321
Very volatile
Days Of Sales Outstanding10767.5979.9019
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.151.0345
Slightly volatile
Price To Book Ratio0.940.9923.6884
Slightly volatile
Fixed Asset Turnover0.380.48.1727
Slightly volatile
Debt Ratio0.230.220.0911
Slightly volatile
Price Sales Ratio16816046.7911
Slightly volatile
Asset Turnover0.00280.0030.1068
Slightly volatile
Price Fair Value0.940.9923.6884
Slightly volatile

Spyre Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap114.2 M142.2 M149.4 M
Very volatile

Spyre Fundamental Market Drivers

Cash And Short Term Investments339.3 M

Spyre Upcoming Events

7th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
7th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Spyre Therapeutics Financial Statements

Spyre Therapeutics stakeholders use historical fundamental indicators, such as Spyre Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Spyre Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Spyre Therapeutics' assets and liabilities are reflected in the revenues and expenses on Spyre Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Spyre Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue594.5 K564.8 K
Total Revenue797.4 K757.5 K
Cost Of Revenue867.6 K1.1 M
Stock Based Compensation To Revenue 26.08  27.38 
Sales General And Administrative To Revenue 40.58  42.61 
Research And Ddevelopement To Revenue 90.92  95.46 
Capex To Revenue 0.02  0.02 
Revenue Per Share 0.14  0.13 
Ebit Per Revenue(314.50)(298.78)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FFord Motor
GMGeneral Motors
SSentinelOne
When determining whether Spyre Therapeutics is a strong investment it is important to analyze Spyre Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Spyre Therapeutics' future performance. For an informed investment choice regarding Spyre Stock, refer to the following important reports:
How To Invest In Spyre
Details
Is Spyre Stock a good investment?
Details
What is Spyre Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Spyre Therapeutics Correlation against competitors.
For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spyre Therapeutics. If investors know Spyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(37.90)
Return On Assets
(0.39)
Return On Equity
(0.92)
The market value of Spyre Therapeutics is measured differently than its book value, which is the value of Spyre that is recorded on the company's balance sheet. Investors also form their own opinion of Spyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spyre Therapeutics' market value can be influenced by many factors that don't directly affect Spyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Spyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY